Identification of Alcohol Biomarker Signatures

The summary for the Identification of Alcohol Biomarker Signatures grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Identification of Alcohol Biomarker Signatures: This Request for Applications (RFA) fosters the utilization of genomic, proteomic, and metabolomic technologies for the development of diagnostic biomarker signatures for alcohol consumption and alcohol-induced tissue injury. Specifically, the research program is aimed at identifying signatures of acute and chronic alcohol consumption for diagnosing high-risk drinking, detecting relapse to drinking, disclosing recent drinking in high risk situations such as pregnancy, as well as signatures for alcohol-induced early tissue damage including brain damage, alcoholic liver disease (ALD), pancreatitis, immune disorders, cancer, cardiomyopathy and other alcohol-induced diseases. Recent advances in high-throughput technologies in genomics, proteomics, and metabolomics, in combination with robust bioinformatics enable researchers to rapidly survey thousands of differentially expressed genes, proteins, or metabolites simultaneously, thus employing an integrative! approach to identify unique biomarker signatures. These state-of-the-art technologies provide a great opportunity to discover a new generation of biomarkers. These signatures could lead to the identification of potential targets for medication development and for evaluating the efficacy of lead compounds in clinical trials. We encourage collaborations from disparate scientific areas and disciplines, including those not traditionally supported by NIAAA combining unique and complementary expertise, techniques, model systems and tissues. It is essential, however, that the proposed activities be within the mission of NIAAA.